Case Studies: Packaging Failures in Real-World Stability Testing
Product: Parenteral injectable in Type I glass vial with aluminum crimp and flip-off cap
Click to read the full article.
Pharmaceutical Containers and Closures for Stability
Reviewing Container Closure Systems in Regulatory Submissions
Container closures protect drug products from environmental exposure, contamination, and physical damage. Any flaw in the CCS—be it sealing, compatibility, or traceability—can lead to product rejection or market recalls. Regulatory bodies view packaging as a critical quality attribute (CQA), and submissions must clearly show how the chosen CCS supports product safety and efficacy.
Click to read the full article.
How to Perform Compatibility Testing for Container Materials
The first step is to understand the product’s formulation and identify risks posed by container materials:
Click to read the full article.
Role of Extractables and Leachables in Container Qualification
Extractables are compounds that can be forced out of container materials using aggressive solvents under exaggerated conditions. They represent the worst-case potential for contamination.
Click to read the full article.
Developing an SOP for Container Selection in Stability Studies
Stability studies are conducted to evaluate how environmental factors affect drug quality over time. The integrity and performance of the container are integral to the reliability of this data. An SOP helps in:
Click to read the full article.
Visual Inspection Criteria for Closures and Seals
Closures (e.g., rubber stoppers, screw caps) and seals (e.g., aluminum crimps, induction seals) are subject to mechanical and material-based failures. Visual inspection helps detect defects such as:
Click to read the full article.
Sterility Considerations for Container Closure Systems
Container closure systems act as the final protective barrier between the drug product and the external environment. For sterile products, any compromise in this barrier can directly lead to contamination and risk to patient health. Regulatory bodies like the USFDA and EMA expect pharmaceutical companies to demonstrate robust sterility assurance via container closure integrity (CCI) testing.
Click to read the full article.
Shelf Life Impact Based on Closure Material Selection
The closure is in direct contact or proximity to the drug product and contributes significantly to the barrier properties of the packaging system. Improper material selection can lead to:
Click to read the full article.
How to Justify Container Choices in Regulatory Submissions
Pharmaceutical containers are not merely passive holders; they directly affect drug product stability, safety, and quality. Regulators expect that the selected container:
Click to read the full article.
Validation of Sealing Processes for Long-Term Stability
Improperly sealed containers can lead to loss of sterility, ingress of moisture or oxygen, and chemical degradation of the active pharmaceutical ingredient (API). This directly affects the product’s shelf life, quality, and patient safety. Key objectives of sealing validation include:
Click to read the full article.